Trial Profile

A phase-1 first-in-human study of TRB-051 for the treatment of autoimmune and inflammatory diseases

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 01 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

01 Jul 2024 New trial record
26 Jun 2024 According to a TRexBio media release, on achieving certain development, regulatory, and commercial milestones across partnered programs like this, TrexBio is eligible to receive more than $1.1 billion.
26 Jun 2024 According to a TRexBio media release, this program is one of three under the research collaboration and exclusive worldwide license agreement between TRexBio and Lilly, which leverages proprietary Deep Biology platform of TrexBio to identify and develop novel therapies for immune-mediated diseases. Pursuant to the agreement, TRexBio has earned a double-digit million dollar milestone payment.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com